JPRN-UMIN000006478已完成2 期
Multicenter Phese II Study of Optimal-XELOX plus Bevacizumab Therapy with Oxaliplatin Stop-and-Go Strategy and Oral capecitabin plus Bevacizumab Maintenance Therapy in Advanced Colorectal Cancer - Phese II Study of Optimal-XELOX plus Bevacizumab Therapy in Advanced Colorectal Cancer (CCOG-0902 Study)
Chubu Clinical Oncology Group (CCOG)0 个研究点目标入组 50 人开始时间: 2011年10月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Previous history of severe drug-induced allergy (2)Brain metastasis (3)Cerebrovascular disease or its symptoms within 1 year. (4)Massive pleural effusion or ascites that required drainage. (5)History of active double cancer. (6)Previous history of thoromboembolitic disease, or necessity for antithrombotic drug. (7)Intestinal bleeding, ileus, bowel obstruction or uncontrolled peptic ulcer. (8)History of gastrointestinal perforation within 1 year. (9)Diathesis of bleeding (history of hemoptysis, including cavitation and/or necrosis in lung metastasis confirmed by imaging), coagulopathy. (10)Severe renal failure or urinary protein (more than 2+). (11)Uncontrolled severe complications (DM, hypertension, diarrhea, et al.). (12)Patient with symptomatic cardiovascular disease or asymptomatic disease but have been treated (>=Grade 2 according to NCI-CTCAE ver.4). History of myocardial infarction within a year. (13)Interstitial lung disease or pulmonary fibrosis. (14)Uncontrolled infection. (15)Patient receiving surgical procedure or such as skin-open biopsy, trauma surgery, or other more intensive surgeries within 4 weeks or aspiration biopsy within a week. (16)Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers. (17)Not appropriate for the study at the physician's assessment.
研究者
相似试验
已完成
2 期
Multicenter Phase II Study of XELOX with Bevacizumab in the Late Elderly Patients with Unresectable Advanced/Recurrent Colorectal Cancercolorectal cancerJPRN-UMIN000003500Epidemiological and Clinical Research Information Network (ECRIN)35
已完成
2 期
Multicenter randomized phase ll study of XELOX plus bevacizumab or XELIRI plusbevacizumab as first-line chemotherapy for metastatic or recurrent colorectal cancerColorectal cancerJPRN-UMIN000007547Chubu Clinical Oncology Group (CCOG)100
已完成
2 期
A randomized phase II study of XELOX plus Bevacizumab versus XELIRI plus Bevacizumab for advanced colorectal cancer with or without mitochondrial transcription factor A (mtTFA) expression.nresectable advanced/recurrent colorectal cancerJPRN-UMIN000005060Fukuoka University Hospital100
已完成
4 期
Observational study of XELOX in combination with bevacizumab for advanced or recurrent colorectal canceradvanced and recurrent colorectal cancerJPRN-UMIN000004971Kyoto Prefectural University of Medicine100
已完成
2 期
Multicenter phase II study of CapeOX (XELOX) with stop-and-go strategy as adjuvant chemotherapy in high-risk Stage II or Stage III colon and rectal cancerHigh-risk Stage II or stage III colon and rectum cancer(above the peritoneal reflection)JPRN-UMIN000012535Chubu Clinical Oncology Group200